DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Aveed is a drug marketed by Endo Pharms Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-two patent family members in thirty-eight countries.
The generic ingredient in AVEED is testosterone undecanoate. There are sixty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There is one tentative approval for the generic drug (testosterone undecanoate), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for AVEED
|Suppliers / Packagers:||1|
|Bulk Api Vendors:||45|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for AVEED|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for AVEED|
|DailyMed Link:||AVEED at DailyMed|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Endo Pharms Inc||AVEED||testosterone undecanoate||INJECTABLE;INTRAMUSCULAR||022219-001||Mar 5, 2014||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Endo Pharms Inc||AVEED||testosterone undecanoate||INJECTABLE;INTRAMUSCULAR||022219-001||Mar 5, 2014||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|